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A B S T R A C T
Background
Schizophrenia is a serious chronic mental illness affecting an estimated 21 million people worldwide and there is increasing evidence
linking inflammation in the brain to the pathophysiology of schizophrenia. Antipsychotic drugs are the conventional treatment for
people with schizophrenia but are not always fully effective. Acetylsalicylic acid (aspirin) is a non-steroidal anti-inflammatory drug
(NSAID) with properties that inhibit the proinflammatory status of the brain. Using aspirin as an adjunct (add-on) treatment to
antipsychotics or as a stand-alone treatment could be a novel, relatively inexpensive option for people with schizophrenia.
Objectives
To review the effects of acetylsalicylic acid (aspirin) as adjunct (add-on) or as stand-alone treatment for people with schizophrenia.
Search methods
We searched the Cochrane Schizophrenia Group’s Trials Register (last search 8 March 2018) which is based on regular searches of
MEDLINE, Embase, PubMed, CINAHL, BIOSIS, AMED, PsycINFO and registries of Clinical Trials. There are no language, date,
document type, or publication status limitations for inclusion of records in the register.
Selection criteria
Randomised clinical trials focusing on aspirin for people with schizophrenia.
Data collection and analysis
We extracted data independently. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval (CI), on an
intention-to-treat (ITT) basis. For continuous data, we estimated the mean difference (MD) between groups and its 95% CI. We
employed a fixed-effect model for analyses. We assessed risk of bias for included studies and created a ’Summary of findings’ table using
GRADE.
Main results
We included two studies, both comparing the effects of adding aspirin to standard antipsychotic treatment with adding placebo
to standard antipsychotic treatment. We were hoping to find high-quality data for seven main outcomes of importance: clinically
important change in global state, mental state, cognitive functioning and quality of life, numbers leaving the study early, incidence
of gastrointestinal adverse events and hospital admission. Clinically important change data were not reported. Global state data were
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reported by one study as ’unspecified problem necessitating change in dose or type of antipsychotics’; there was no clear difference
between treatment groups for this outcome (RR 0.75, 95% CI 0.30 to 1.88; studies = 1; participants = 70; very low-quality evidence).
Both trials measured mental state using the Positive and Negative Symptom Scale (PANSS), and mean total PANSS endpoint scores
favoured the adjunct aspirin group in the medium term (MD -6.56, 95% CI -12.04 to -1.08; studies = 2; participants = 130; very low-
quality evidence). Less than 10% of each group’s participants left the studies early (for any reason) and by around three months there
was no clear difference between numbers leaving early from the aspirin group compared to numbers leaving early from the placebo
group suggesting aspirin is acceptable (RR 1.12, 95% CI 0.40 to 3.14; studies = 2; participants = 130; very low-quality evidence). There
was some gastric upset in both groups but rates were not clearly different between the treatment groups (RR 1.03, 95% CI 0.55 to 1.94;
studies = 1; participants = 70; very low-quality evidence). We are unclear if ’change in hospital status’ is an unfavourable outcome or
not as one study reported equivocal data (RR 0.56, 95% CI 0.05 to 5.90; studies = 1; participants = 70; very low-quality evidence). It
should be noted that all the above results were based on data of very low-quality and were difficult to interpret for clinicians or patients,
and that the two studies, completed in the last decade, failed to report any usable outcomes on cognitive functioning or quality of life.
Authors’ conclusions
We highlighted the evidence that some pioneering researchers feel this question is important enough to merit testing in randomised
trials. However, we also highlighted that the evidence produced from these trials was weak and inconclusive. It was impossible to draw
clear conclusions on the therapeutic value of aspirin for schizophrenia from these short, small and limited trials.
P L A I N L A N G U A G E S U M M A R Y
Aspirin as an add-on treatment to antipsychotics for people schizophrenia
Background
Schizophrenia is a serious mental illness that affects around 21 million people worldwide. The symptoms of schizophrenia are typically
classified into positive (e.g. hallucinations and delusional thoughts), negative (e.g. withdrawal and difficulty with social interaction) and
cognitive (e.g. poor attention and restricted working memory) groups. These symptoms cause distortions in an individual’s behaviour,
thinking, emotions, sense of self and perception. Usually, antipsychotic medicines are used for treating the symptoms of schizophrenia.
In recent years, inflammation (swelling) in a person’s brain was linked to the symptoms that accompany schizophrenia. Aspirin is an
affordable medicine which acts against inflammation and, therefore, it is thought it could help reduce the symptoms of schizophrenia.
In this review, we looked at the effects of using aspirin as an add-on treatment for people with schizophrenia.
Study characteristics
After searching Cochrane Schizophrenia’s database in March 2018 and assessing the search results, we included one randomised
controlled trial (clinical studies where people are randomly put into one of two or more treatment groups) from the Netherlands (70
participants) and one from Iran (60 participants). Both trials used aspirin as an add-on treatment to standard antipsychotic medication
and compared it with placebo (a dummy treatment), also as an add-on to standard treatment.
Key results
Participants receiving aspirin had slightly better results for their mental state, which was measured with the Positive and Negative
Symptom Scale (PANSS). For side effects related to stomach problems, there seemed to be no clear difference between the groups. The
same applied to changes in hospital status and leaving the study early. However, all these results were based on analyses of very poor
data and graded as very low-quality evidence. No trial gave usable information on cognitive functioning or quality of life.
Quality of the evidence
This review was based on results from only two small trials, which made it impossible to say whether aspirin would be a good treatment
option for people with schizophrenia. More information from the trials that are underway could strengthen the results of this analysis.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Aspirin + antipsychotics compared to placebo + antipsychotics for people with schizophrenia
Patient or population: people with schizophrenia
Setting: inpat ients and outpat ients
Intervention: aspirin + ant ipsychot ics
Comparison: placebo + antipsychot ics
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo + an-
tipsychotics
Risk with aspirin + an-
tipsychotics
Global state: any
change in global state
- unspecif ied problem
necessitat ing change in
dose or type of ant ipsy-
chot ics - medium term
243 per 1000 182 per 1000
(73 to 457)
RR 0.75
(0.30 to 1.88)
70
(1 RCT)
⊕©©©
Very lowa,b,c
Data for our prede-
f ined outcome, clini-
cally important change
in global state, were
not reported. Data on
global state outcomes
were very sparse. This
was the only outcome
in the global state do-
main
Mental state: general
- mean endpoint score
(PANSS total, high =
poor) - medium term
- MD in the intervent ion
group was 6.56 lower
(12.04 lower to 1.08
lower)
- 130
(2 RCTs)
⊕©©©
Very lowb,c,d
Data for our predef ined
outcome, clinically im-
portant change in men-
tal state were not re-
ported
Cog-
nitive functioning: clin-
ically important change
in cognit ive funct ioning
See comment See comment - - - Unable to retrieve us-
able data on this out-
come.
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Leaving the study
early: short-term - for
any reason
105 per 1000 118 per 1000
(42 to 331)
RR 1.12
(0.40 to 3.14)
130
(2 RCTs)
⊕©©©
Very lowa,b
-
Adverse events: gas-
trointestinal - dyspep-
t ic symptoms - self -as-
sessed as at least ’mod-
erate’
405 per 1000 418 per 1000
(223 to 786)
RR 1.03
(0.55 to 1.94)
70
(1 RCT)
⊕©©©
Very lowa,b
Combined data for self -
assessed ’moderate’,
’serious’ and ’very se-
rious’ symptoms. Ac-
cording to the study’s
authors, there were
no complaints requir-
ing medical attent ion.
Data on adverse events
were sparse and re-
ported only in 1 study
Quality of life: clinically
important change
- - - - - We were unable to re-
trieve any outcomes re-
lated to quality of lif e
Service use: change in
hospital status - any
change
54 per 1000 30 per 1000
(3 to 319)
RR 0.56
(0.05 to 5.90)
70
(1 RCT)
⊕©©©
Very lowa,b,c
Data for our predef ined
outcome ’hospital ad-
mission’ were not re-
ported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; MD: mean dif ference; PANSS: Posit ive and Negative Symptom Scale; RCT: randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a Imprecision: downgraded two levels for small sample size or wide conf idence intervals, or both.
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bPublicat ion bias: downgraded one level since a number of unpublished trials were ident if ied in search. Number of trials
included for this outcome was very low.
cIndirectness: downgraded one level as outcomes were proxy measures of what had been prest ipulated within the original
protocol for this review.
d Imprecision: downgraded one level for small sample size.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Schizophrenia is a chronic serious mental illness affecting an es-
timated 21 million people worldwide (WHO 2018). Individuals
are typically diagnosed with schizophrenia following assessment
of their behaviour to determine their mental state and to rule out
other possible causes such as substance abuse or another medical
condition (Barbato 1998). The symptoms of schizophrenia are
typically classified into positive, negative and cognitive groups.
Positive symptoms are characteristic of schizophrenia and include
hallucinations and delusional thoughts, while negative symptoms
include diminished motivation, withdrawal and difficulty with so-
cial interaction (WHO 2018). Cognitive symptoms include lim-
ited executive functioning, poor attention and restricted working
memory which results in an inability to organise simple tasks and
work sequentially and effectively (Simpson 2010). These symp-
toms cause distortions in an individual’s behaviour, thinking, emo-
tions, sense of self and perception (WHO 2018).
Recovery from the symptoms of schizophrenia varies between indi-
viduals. Research has shown that 45% of people with schizophre-
nia will recover after one or more episodes, 35% will experience
a mixed pattern of remission and relapse, while a further 20%
will present unremitting symptoms and disability (Barbato 1998).
Individuals diagnosed with schizophrenia frequently experience
stigma and discrimination, and are estimated to die 12 to 15 years
earlier than the mean population (van Os 2009). The specific ori-
gins of schizophrenia have yet to be identified; however, several
possible causes have been recognised. These include several neu-
rotransmitter dysfunctions involving dopaminergic, glutamater-
gic and gamma-aminobutyric acid (GABA)ergic signalling, indi-
cations of disturbances in neuron myelination, impairments to
the functioning of the brain’s prefrontal cortex and increasing ev-
idence linking inflammation in the brain to the pathophysiology
of schizophrenia (Kroken 2014; Smyth 2013).
Description of the intervention
Antipsychotic drugs are the mainstay of treatment for schizophre-
nia, and include the conventional ’typical’ antipsychotics, chlor-
promazine, haloperidol, perphenazine and fluphenazine, and sec-
ond-generation ’atypical’ antipsychotics such as risperidone, arip-
iprazole, ziprasidone and olanzapine. Antipsychotics are primarily
effective in the treatment of positive symptoms, but have demon-
strated small effect sizes in the treatment of the cognitive symp-
toms of schizophrenia which are evident prior to the development
of psychosis and often remain once the symptoms of psychosis
have been treated (Kroken 2014).
Growing awareness of the role of inflammation in the develop-
ment of schizophrenia has resulted in research to identify pos-
sible additional molecular therapeutic targets, including adjunc-
tive treatment options involving non-steroidal anti-inflammatory
drugs (NSAIDs) such as acetylsalicylic acid (aspirin) (Berk 2013).
Aspirin is an inexpensive World Health Organization essential
medicine that is commonly used as a treatment for mild to mod-
erate pain and inflammation. In addition to its anti-inflammatory
properties, aspirin contributes to the prevention of myocardial in-
farction, stroke and dementia, but is not widely used as a con-
ventional treatment for schizophrenia. Aspirin is taken orally at
varying doses depending on the condition being treated, with a
typical dose of 0.3 g to 1 g repeated every four hours according to
clinical needs, up to a maximum of 4 g daily (some inflammatory
diseases may require a higher dose) (Reynolds 1982).
How the intervention might work
Anti-inflammatory agents such as aspirin possess properties which
inhibit the proinflammatory status of the brain. Neuroinflam-
mation triggers microglial activation resulting in the produc-
tion of inflammatory molecules which include cytokines, phago-
cytotic cells/proteins and disruption of the blood-brain barrier
(Kirkpatrick 2013). Blood serum levels of the cytokine interleukin
(IL)-6 are raised for individuals experiencing a first episode of
schizophrenia and those in acute relapse (Miller 2011). Stimula-
tion of proinflammatory cytokines may activate pathways which
play a role in the regulation of serotonin, glutamate and dopamine
(Benros 2014), with interactions between the IL-6 and dopamine
pathways noted (Girgis 2014).
Cyclooxygenase (COX) is a key enzyme in the biosynthesis of
molecules such as prostaglandins and thromboxanes, which in
turn modulate the production of inflammatory cytokines (Nitta
2013). Aspirin inhibits the production of the COX-1 enzyme
and modifies the activity of COX-2, thereby interrupting the
neurotoxic inflammatory cascade and suppressing the produc-
tion of prostaglandins, thromboxanes and other inflammatory
molecules including cytokines (Berk 2013; Laan 2008). Adverse
effects caused by aspirin include gastric ulcers and bleeding.
Why it is important to do this review
Individuals with schizophrenia identified as having higher levels of
inflammatory markers may benefit from the development of ad-
ditional therapeutic targets, and this review investigated whether
aspirin as an adjunctive treatment offers a beneficial treatment op-
tion in combination with antipsychotics. One meta-analysis in-
vestigated several anti-inflammatory agents (including celecoxib,
davunetide, fatty acids, oestrogens, minocycline, N-acetylcysteine
and aspirin) as adjunctive treatments for schizophrenia (Sommer
2014). This review focused on establishing whether aspirin is an
effective intervention for the treatment of schizophrenia and in-
cluded data from published randomised controlled trials.
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O B J E C T I V E S
To review the effects of acetylsalicylic acid (aspirin) as adjunct (add-
on) or as stand-alone treatment for people with schizophrenia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials. If a trial was described
as ’double-blind’ but implied randomisation, we would have in-
cluded such trials in a sensitivity analysis (see Sensitivity analysis).
We excluded quasi-randomised studies, such as those allocating
by alternate days of the week.
Types of participants
Adults aged 18 years or over with a diagnosis of schizophrenia or
related disorders, including schizophreniform disorder, schizoaf-
fective disorder and delusional disorder using any diagnostic cri-
teria. We included trials where the majority (over 50%) of partic-
ipants had a diagnosis of schizophrenia.
We aimed to ensure information contained in this review was
as relevant to the current care of people with schizophrenia as
possible. Where information was available, we clearly highlighted
the current clinical state (acute, early postacute, partial remission,
remission), stage of illness (prodromal, first episode, early illness,
persistent) and whether the studies primarily focused on people
with specific disorders (e.g. treatment-resistant illness or negative
symptoms).
Types of interventions
1. Acetylsalicylic acid (aspirin)
Aspirin administered by any means of delivery or dose (adjunct
or stand-alone treatment). We would have reported separate com-
parisons for when aspirin was used as part of an adjunct treatment
and for when it was used as sole treatment.
2. Placebo
Active or inactive placebo treatments administered by any means
of delivery or dose (adjunct or stand-alone treatment).
3. Any antipsychotic treatment (adjunct or stand-alone
treatment)
Types of outcome measures
We divided all outcomes into short-term (up to eight weeks),
medium term (eight weeks to six months) and long term (six
months or longer).
We endeavoured to report binary outcomes recording clear and
clinically meaningful degrees of change (e.g. global impression of
much improved, or more than 50% improvement on a rating scale
- as defined within the trials) before any others. Thereafter, we
listed other binary outcomes and then those that were continuous.
For outcomes such as ’clinically important change’, ’any change’
and ’relapse’, we used the definition used by each of the trials.
For valid scales, see Data extraction and management.
Primary outcomes
1. Global state
1.1 Clinically important change in global state (for example,
at least 50% change in Clinical Global Impressions Scale
(CGI)
2. Mental state
2.1 Clinically important change in mental state
3. Cognitive functioning
3.1 Clinically important change in cognitive functioning
Secondary outcomes
1. Global state
1.1 Any change in global state
1.2 Relapse
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1.3 Average endpoint or change score on global state scale
2. Mental state
2.1 General symptoms.
2.1.1 Any change in mental state
2.1.2 Average endpoint or change score on general mental state
scale
2.2 Specific symptoms - average endpoint or change score on
specific symptoms scale
2.2.1 Positive symptoms (e.g. delusions, hallucinations).
2.2.2. Negative symptoms (e.g. avolition, blunted affect).
2.2.3. Mood (e.g. anxiety, depression).
2.2.4. Other psychotic symptoms (e.g. disorganised thought).
3. Cognitive functioning
3.1. General
3.1.1. Clinically important change in general cognitive function-
ing
3.1.2. Any change in general cognitive functioning
3.1.3. Average endpoint or change score on general cognitive func-
tioning scale
3.2. Specific
3.2.1. Clinically important change in specific cognitive function-
ing
3.2.2. Any change in specific cognitive functioning.
3.2.3. Average endpoint or change score on specific cognitive func-
tioning scale
4. Functioning
4.1. General functioning
4.1.1. Clinically important change in general functioning
4.1.2. Average endpoint in general functioning
4.1.3. Average endpoint or change score on general functioning
scale
4.2. Specific functioning
4.2.1. Clinically important change in specific functioning
4.2.2. Any change in specific functioning.
4.2.3. Average endpoint or change score on specific functioning
scale.
5. Behaviour
5.1. General behaviour
5.1.1. Clinically important change in general behaviour
5.1.2. Any change in general behaviour.
5.1.3. Average endpoint or change score on general behaviour scale
5.2. Specific behaviour
5.2.1. Clinically important change in specific behaviour
5.2.2. Any change in specific behaviour.
5.2.3. Average endpoint or change score on specific behaviour scale
6. Leaving the study early
6.1 Leaving the study early due to adverse effects
6.2 Leaving the study early for poor clinical effect
7. Adverse events
7.1 General adverse events (measured as scores or binary)
7.2 Specific adverse events (measured as scores or binary)
7.2.1 Allergic reactions.
7.2.2 Gastrointestinal (nausea, vomiting, diarrhoea, bleeding)
7.2.3 Weight gain.
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8. Quality of life
8.1 Clinically important change in quality of life
8.2 Any change in quality of life measure
8.3 Average endpoint or change score on quality of life scale
9. Service use
9.1 Hospital admission
9.2 Days in hospital
9.3 Change in hospital status
10. Inflammation markers
10.1 C-reactive protein levels in blood plasma
10.2 Cytokine levels
11. Economic
11.1 Direct costs
11.2 Indirect costs
’Summary of findings’ table
We used the GRADE approach to interpret findings (Schünemann
2011), GRADEpro GDT to export data from our review and
Review Manager 2014 to create a ’Summary of findings’ table.
These tables provide outcome-specific information concerning the
overall quality of evidence from each included study in the com-
parison, the magnitude of effect of the interventions examined and
the sum of available data on all outcomes we rated as important to
patient care and decision making. We selected the following main
outcomes for inclusion in our ’Summary of findings’ table: and
preferred these to be for medium term (eight weeks to six months).
• Global state - clinically important change in global state.
• Mental state - clinically important change in mental state.
• Cognitive functioning - clinically important change in
general cognitive functioning.
• Leaving the study early - for any reason.
• Adverse events - gastrointestinal (e.g. nausea, vomiting,
diarrhoea).
• Quality of life - clinically important change in quality of life
• Service use - hospital admission.
If data were not available for these prespecified outcomes but were
available for ones that were similar, we presented the closest out-
come to the prespecified one in the table but took this into account
when grading the finding.
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group’s Study-Based Register of
Trials
On 24 March 2016, 29 June 2017 and 8 March 2018, the Infor-
mation Specialist searched this register using the following search
strategy:
*Acetylsalicylic Acid (Aspirin)* in Intervention Field of STUDY
In such a study-based register, searching the major concept re-
trieves all the synonyms and relevant studies because all the stud-
ies have already been organised based on their interventions and
linked to the relevant topics (Shokraneh 2017).
This register is compiled by systematic searches of major resources
(MEDLINE, Embase, AMED, BIOSIS, CENTRAL, CINAHL,
ClinicalTrials.Gov, PsycINFO, PubMed, and World Health Or-
ganization (WHO) ICTRP) and their monthly updates, Pro-
Quest Dissertations and Theses A&I and its quarterly update,
Chinese databases (CBM, CNKI and Wanfang) and their annual
updates, handsearches, grey literature and conference proceedings
(see Group’s Module). There is no language, date, document type
or publication status limitations for inclusion of records into the
register.
Searching other resources
1. Reference searching
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We inspected references of all included studies for further relevant
studies.
2. Personal contact
We contacted the first author of each included study for informa-
tion regarding unpublished trials, but found no further trials.
Data collection and analysis
Selection of studies
For the 2016 search, Tracey Roberts (TR) independently inspected
citations from the searches and identified relevant abstracts (see
Acknowledgements). Two review authors (LS and JF) indepen-
dently reinspected all to ensure reliability. There were no disputes,
but we would have acquired the full report for more detailed
scrutiny. TR obtained and inspected full reports of the abstracts
meeting the review criteria. Three review authors (LS, EP and JF)
independently reinspected these full reports to ensure reliable se-
lection. For the 2017 and 2018 searches, three review authors (LS,
EP and JF) independently inspected citations. We summarised
trial selection in a PRISMA flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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Data extraction and management
1. Extraction
The review authors (LS and EP) independently extracted data from
the included studies. TR and one review author (LS) inputted the
data and one review author (EP) checked it. Two review authors
(LS and EP) would have discussed any disagreements. If needed,
we contacted study authors through an open-ended request to ob-
tain missing information or for clarification. Two review authors
(LS and EP) received replies from Laan 2010. Furthermore, we
contacted all authors of ongoing studies and studies awaiting as-
sessment and discussed replies in the Results section (see ’Studies
awaiting assessment’ and ’Ongoing studies’).
2. Management
2.1 Forms
We extracted data onto standard, simple forms.
2.2 Scale-derived data
We included continuous data from rating scales only if:
• the psychometric properties of the measuring instrument
had been described in a peer-reviewed journal (Marshall 2000);
• the measuring instrument had not been written or modified
by one of the trialists for that particular trial and
• the instrument had a global assessment of an area of
functioning and not subscores which are not, in themselves,
validated or shown to be reliable. However, there were
exceptions, we included subscores from mental state scales
measuring positive and negative symptoms of schizophrenia.
Ideally the measuring instrument should have been: 1. a self-re-
port or 2. completed by an independent rater or relative (not the
therapist). We realise that this is not often reported clearly and we
noted if this was the case or not in Risk of bias in included studies
and Characteristics of included studies table.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. In contrast, calculation of change needs two assess-
ments (baseline and endpoint), which can be difficult in unsta-
ble and difficult-to-measure conditions such as schizophrenia. We
primarily used endpoint data, and only used change data if the
former were not available. We combined endpoint and change
data in the analysis as we aimed, wherever possible, to use the
mean differences (MD) rather than standardised mean differences
(SMD) throughout (Deeks 2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we applied the following standards.
For larger studies (more than 200 participants) and change
data
We would have entered data from studies of at least 200 partici-
pants into the analysis irrespective of the following rules, because
skewed data pose less of a problem in large studies. We also would
have entered change data, as when continuous data are presented
on a scale that includes a possibility of negative values (such as
change data), it is difficult to determine whether such data are
skewed or not. We would have presented and entered change data
into statistical analyses.
For endpoint data from smaller studies (fewer than 200
participants)
• When a scale starts from the nite number zero, we
subtracted the lowest possible value from the mean, and divide
this by the standard deviation (SD). If this value is lower than 1,
it strongly suggests a skew and we would have excluded these
data. If this ratio is higher than 1 but below 2, there is suggestion
of skew. We entered these data and tested whether their inclusion
or exclusion changed the results substantially. Finally, if the ratio
is larger than 2 we included these data, because skew is less likely
(Altman 1996).
• If a scale starts from a positive value (such as the Positive
and Negative Syndrome Scale (PANSS; Kay 1986), which can
have values from 30 to 210), we modified the calculation
described above to take the scale starting point into account. In
these cases, skew is present if 2 SD > (S - Smin), where S is the
mean score and Smin is the minimum score.
2.5 Common measure
To facilitate comparison between trials, we intended, where pos-
sible, to convert variables that could be reported in different met-
rics, such as days in hospital (mean days per year, per week or per
month) to a common metric (e.g. mean days per month).
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2.6 Conversion of continuous to binary
Where possible, we attempted to convert outcome measures to di-
chotomous data. This can be done by identifying cut-off points on
rating scales and dividing participants accordingly into ’clinically
improved’ or ’not clinically improved’. It is generally assumed that
if there is a 50% reduction in a scale-derived score such as the Brief
Psychiatric Rating Scale (BPRS; Overall 1962) or the PANSS (Kay
1986), this could be considered as a clinically significant response
(Leucht 2005a; Leucht 2005b). If data based on these thresholds
were not available, we used the primary cut-off presented by the
original authors.
2.7 Direction of graphs
Where possible, we entered data in such a way that the area to the
left of the line of no effect indicated a favourable outcome for as-
pirin. Where keeping to this made it impossible to avoid outcome
titles with clumsy double-negatives (e.g. ’Not unimproved’), we
reported data where the left of the line indicated an unfavourable
outcome for aspirin and made a note in the relevant graphs.
Assessment of risk of bias in included studies
Three review authors (LS, EP and TR) independently assessed
risk of bias using criteria described in the Cochrane Handbook for
Systematic Reviews of Interventions to assess trial quality (Higgins
2011a). This set of criteria is based on evidence of associations
between overestimate of effect and high risk of bias of the article,
in domains such as sequence generation, allocation concealment,
blinding, incomplete outcome data and selective reporting.
Two review authors (LS and EP) made the final rating by consen-
sus, with the involvement of a third review author (JF). Where
there were inadequate details of randomisation and other charac-
teristics of trials, two review authors (LS and EP) contacted authors
of the studies to request further information. If disputes arose as
to which category a trial was to be allocated, we resolved these by
discussion.
We noted the level of risk of bias in the Risk of bias in included
studies; ’Risk of bias’ table; Figure 2; Figure 3; and Summary of
findings for the main comparison.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Measures of treatment effect
1. Binary data
For binary outcomes, we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RR is more intuitive (Boissel 1999) than odds ratios
and that odds ratios tend to be interpreted as RR by clinicians
(Deeks 2000).
2. Continuous data
For continuous outcomes, we estimated mean difference (MD)
between groups. We preferred not to calculate effect size measures
(SMD). However, if scales of very considerable similarity had been
used, we would have presumed there was a small difference in mea-
surement, and would have calculated effect size and transformed
the effect back to the units of one or more of the specific instru-
ments.
Unit of analysis issues
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1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. First, authors often fail to account
for intraclass correlation in clustered studies, leading to a ’unit of
analysis’ error (Divine 1992), whereby P values are spuriously low,
CIs unduly narrow and statistical significance overestimated. This
causes type I errors (Bland 1997; Gulliford 1999).
Where clustering is not accounted for in primary studies, we would
have presented data in a table, with a (*) symbol to indicate the
presence of a probable unit of analysis error. We planned to contact
first authors of studies to obtain intraclass correlation coefficients
(ICCs) for their clustered data and to adjust for this by using
accepted methods (Gulliford 1999).
Where clustering had been incorporated into the analysis of pri-
mary studies, we would have presented these data as if from a non-
cluster randomised study, but adjusted for the clustering effect.
We sought statistical advice and have been advised that the binary
data as presented in a report should be divided by a ’design effect’.
This is calculated using the mean number of participants per clus-
ter (m) and the ICC [design effect = 1 + (m - 1) × ICC] (Donner
2002). If the ICC was not reported, we would have assumed it to
be 0.1 (Ukoumunne 1999).
If cluster studies had been appropriately analysed taking into ac-
count ICCs and relevant data documented in the report, synthe-
sis with other studies would be possible using the generic inverse
variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. This
occurs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the first phase is carried over to the
second phase. As a consequence, on entry to the second phase
the participants can differ systematically from their initial state,
despite a washout phase. For the same reason, cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne
2002). As both effects are very likely in severe mental illness, we
would have only used data from the first phase of cross-over stud-
ies.
3. Studies with multiple treatment groups
Where a study involved more than two treatment arms, if rele-
vant, we would have presented the additional treatment arms in
comparisons. If data were binary, we would have simply added
and combined within the two-by-two table. If data were contin-
uous, we would have combined data following the formula in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011b). Where the additional treatment arms were not relevant,
we would not have reproduced these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). We chose that, for any particular outcome, should more
than 50% of data be unaccounted for, we would not reproduce
these data or use them within analyses. However, if more than
50% of those in one arm of a study were lost, but the total loss was
less than 50%, we would have addressed this within the ’Summary
of findings’ table by downgrading quality. Finally, we would also
have downgraded quality within the ’Summary of findings’ table
should loss have been 25% to 50% in total.
2. Binary
In the case where attrition for a binary outcome was between 0%
and 50% and where these data were not clearly described, we
presented data on a ’once-randomised-always-analyse’ basis (an
ITT analysis). Those leaving the study early were all assumed to
have the same rates of negative outcome as those who completed,
with the exception of the outcome of death and adverse effects.
For these outcomes, we used the rate of those who stay in the study
- in that particular arm of the trial - for those who did not. We
planned, where possible, to undertake a sensitivity analysis testing
how prone the primary outcomes were to change when data only
from people who complete the study to that point were compared
to the ITT analysis using the above assumptions.
3. Continuous
3.1 Attrition
Where attrition for a continuous outcome was between 0% and
50%, and data only from people who complete the study to that
point were reported, we reproduced these.
3.2 Standard deviations
If SDs were not reported, we would have tried to obtain the miss-
ing values from the authors. If they were not available, where
there were missing measures of variance for continuous data, but
an exact standard error (SE) and CIs available for group means,
and either P value or t value available for differences in mean, we
could have calculated them according to the rules described in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011b). When only the SE is reported, SDs are calculated by the
formula SD = SE * square root (n). The Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011b) presents de-
tailed formulae for estimating SDs from P values, t or F values,
CIs, ranges or other statistics. If these formulae did not apply, we
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would have calculated the SDs according to a validated imputation
method which is based on the SDs of the other included studies
(Furukawa 2006). Although some of these imputation strategies
can introduce error, the alternative would have been to exclude
a given study’s outcome and thus to lose information. We never-
theless would have examined the validity of the imputations in a
sensitivity analysis excluding imputed values.
3.3 Assumptions about participants who left the trials early
or were lost to follow-up
Various methods are available to account for participants who left
the trials early or were lost to follow-up. Some trials just present
the results of study completers, others use the method of last ob-
servation carried forward (LOCF), while more recently methods
such as multiple imputation or mixed-effects models for repeated
measurements (MMRM) have become more of a standard. While
the latter methods seem to be somewhat better than LOCF (Leon
2006), we consider that the high percentage of participants leaving
the studies early and differences in the reasons for leaving the stud-
ies early between groups is often the core problem in randomised
schizophrenia trials. Therefore, we did not exclude studies based
on the statistical approach used. However, we preferably would
have used the more sophisticated approaches; that is, MMRM or
multiple imputation to LOCF and we would only present com-
pleter analyses if some type of ITT data was not available at all.
Moreover, we addressed this issue in the item ’Incomplete out-
come data’ of the ’Risk of bias’ tool.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We inspected all stud-
ies for clearly outlying people or situations which we had not pre-
dicted would arise. When such situations or participant groups
arose, we would have discussed these in the text.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We inspected
all studies for clearly outlying methods which we had not predicted
would arise. When such methodological outliers arose, we would
have discussed these in the text.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I2 statistic
We investigated heterogeneity between studies by considering the
I2 statistic alongside the Chi2 P value. The I2 statistic provides an
estimate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed value of
the I2 statistic depends on: 1. magnitude and direction of effects
and 2. strength of evidence for heterogeneity (e.g. value from Chi
2 test, or a CI for the I2 statistic). We interpreted an I2 estimate
greater than or equal to around 50% accompanied by a statistically
significant Chi2 statistic as evidence of substantial levels of hetero-
geneity (Cochrane Handbook for Systematic Reviews of Interventions;
Deeks 2011)). When there were substantial levels of heterogeneity,
we noted these, and for primary outcomes, would have explored
reasons for heterogeneity (Subgroup analysis and investigation of
heterogeneity).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Section 10.1 of the Cochrane Handbook for
Systematic Reviews of Interventions (Sterne 2011).
1. Protocol versus full study
We attempted to locate protocols of the included trials. If the
protocol was available, we compared outcomes in the protocol with
those in the published report. If the protocol was not available,
we compared outcomes listed in the methods section of the trial
report with the actually reported results.
2. Funnel plot
We are aware that funnel plots may be useful in investigating
reporting biases but are of limited power to detect small-study
effects. We did not intend to use funnel plots for outcomes where
there were 10 or fewer studies, or where all studies were of similar
size. In other cases, where funnel plots were possible, we would
have sought statistical advice in their interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. However, there is a disadvantage to the
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random-effects model. It puts added weight onto small studies
which often are the most biased. Depending on the direction of
effect these studies can either inflate or deflate the effect size. We
used a fixed-effect model for analyses.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1 Primary outcomes
There were not enough studies available to justify completing any
subgroup analysis in this review.
1.2 Clinical state, stage or problem
We proposed to undertake this review and provide an overview
of the effects of aspirin for people with schizophrenia in general.
In addition, however, we intended to report data on subgroups of
people in the same clinical state, stage and with similar problems.
2. Investigation of heterogeneity
We reported if inconsistency was high. First, we investigated
whether data had been entered correctly. Second, if data were cor-
rect, we visually inspected the graph and successively removed
studies outside of the company of the rest to see if homogeneity
was restored. For this review, we decided that should this occur
with data contributing to the summary finding of no more than
around 10% of the total weighting, we would have presented such
data. If not, we would have pooled data and discussed the issues.
We know of no supporting research for this 10% cut-off but are
investigating use of prediction intervals as an alternative to this
unsatisfactory state.
When unanticipated clinical or methodological heterogeneity
were obvious we would have stated hypotheses regarding these for
future reviews or versions of this review. We did not undertake
analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
We would have included trials in a sensitivity analysis if they were
described in some way as to imply randomisation. For the primary
outcomes, we would have included these studies and if there was
no substantive difference when the implied randomised studies
were added to those with better descriptions of randomisation,
then we would have employed all relevant data from these studies.
2. Assumptions for lost binary data
Where assumptions had to be made regarding people lost to follow-
up (see Dealing with missing data), we compared the findings of
the primary outcomes when we used our assumption compared
with completer data only. If there was a substantial difference, we
would have reported results and discussed them but continued to
employ our assumption.
Where assumptions had to be made regarding missing SD data (see
Dealing with missing data), we would have compared the findings
on primary outcomes when we used our assumption compared
with completer data only. We would have undertaken a sensitivity
analysis testing how prone results were to change when completer
data only were compared to the imputed data using the above
assumption. If there was a substantial difference, we would have
reported results and discussed them but continued to employ our
assumption.
3. Risk of bias
We would have analysed the effects of excluding trials that were at
high risk of bias across one or more of the domains of randomisa-
tion (Assessment of risk of bias in included studies) for the meta-
analysis of the primary outcome. If the exclusion of trials at high
risk of bias did not substantially alter the direction of effect or the
precision of the effect estimates, then we would have included all
relevant data from these trials in the analysis.
4. Imputed values
We planned to undertake a sensitivity analysis to assess the effects
of including data from trials where we used imputed values for
ICC in calculating the design effect in cluster randomised trials.
If there were substantial differences in the direction or precision
of effect estimates in any of the sensitivity analyses listed above,
we would not have pooled data from the removed trials with the
other trials contributing to the outcome, but would have presented
them separately.
5. Fixed-effect and random-effects models
We synthesised all data using a fixed-effect model; however, we
also synthesised data for the primary outcome using a random-
effects model to evaluate whether this altered the significance of
the results. If there had been a difference, we would have noted
this in the text.
R E S U L T S
Description of studies
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For a substantive description of studies, see Characteristics of
included studies and Characteristics of excluded studies tables.
Results of the search
In the original search, we found 20 records that were potentially
relevant and gained one more through personal communication.
We assessed all 21 full-text papers for eligibility. We then grouped
these into ’studies’ where several of the reports referred to the same
trial (Figure 1). It was possible to include two studies (Attari 2017;
Laan 2010; nine publications)
Included studies
The two studies investigated the same comparison (aspirin plus
antipsychotics versus placebo plus antipsychotics).
1. Methods
Both studies had a randomised, controlled parallel design and used
stratification before randomisation. Laan 2010 was double blind,
while Attari 2017 was described as triple blind.
2. Length of trials
Both included in this review studies were conducted over the
medium term (eight weeks to six months). Both studies also re-
ported outcomes for the short term (up to eight weeks).
3. Participants
Both studies included men and women with Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)
schizophrenia or schizophrenia spectrum disorder. All participants
were receiving antipsychotics. Mean age and inclusion/exclusion
criteria were similar in both studies. Combined baseline PANSS
scores for all groups in Attari 2017 were higher (mean 131, SD
33) compared with Laan 2010 (mean 72, SD 10).
4. Setting
Laan 2010 was a multi-centre trial and included inpatients and
outpatients based in 10 psychiatric hospitals throughout the
Netherlands. Attari 2017 included people referred to a psychiatric
hospital or emergency department in Iran. However, it was not
reported whether these were inpatients or outpatients.
5. Study size
In total, both studies randomised 130 participants (60 in Attari
2017; 70 in Laan 2010).
6. Interventions
Both studies compared antipsychotics and adjunct aspirin with
antipsychotics and placebo. Participants in both studies also re-
ceived gastric protection.
Laan 2010 had two parallel arms. Participants in the experimental
arm (33 at start of trial) received their regular daily antipsychotics,
oral adjunct aspirin 1000 mg/day, and pantoprazole 40 mg/day
for gastric protection. The control arm (37 at start of study) also
received regular daily antipsychotics plus oral placebo and panto-
prazole 40 mg/day for gastric protection. Olanzapine, clozapine
and risperidone were described as the antipsychotics used by most
of the participants.
Attari 2017 had three parallel arms, with 20 participants allocated
to each arm. All participants received their regular antipsychotics
in a dose equivalent to chlorpromazine 100 mg/day (35× risperi-
done, 18× olanzapine, 4× haloperidol, 3× chlorpromazine), and
omeprazole 20 mg/day for gastric protection. In addition, partic-
ipants in the first experimental arm received oral adjunct aspirin
325 mg/day, participants in the second experimental arm received
oral adjunct aspirin 500 mg/day and participants in the control
arm received an oral placebo tablet.
7. Outcomes
7.1 Outcome scales
The trials used a variety of scales to measure outcomes. Those
reporting useable data are described below.
a. Positive and Negative Symptom Scale (PANSS)
The PANSS (Kay 1986) was developed from the BPRS and the
Psychopathology Rating Scale. It is used to evaluate the positive,
negative and general symptoms in schizophrenia. The scale has 30
items, and each item is rated on a 7-point scoring system varying
from ’absent’ (1) to ’extreme’ (7). Higher scores indicate more
pronounced symptomatology.
b. Likert scale for dyspeptic complaints
The 5-point Likert scale is an instrument to measure severity of
gastrointestinal symptoms (Veldhuyzen Van Zanten 1993). It is
comprised of eight questions. The self-reported symptoms can be
rated from ’No problem’ (1) to ’Very severe problem, markedly
influences your daily activities and/or requires rest’ (5). Laan 2010
used this scale to measure dyspeptic complaints. However, these
events were reported as the binary outcomes ’moderate’, ’serious’
and ’very serious’ dyspeptic symptoms, relating to 3 of the 5 end-
points of this scale.
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8. Missing outcomes
These small studies failed to assess or report many outcomes that
could have been of interest. We prespecified some outcomes we
believe are important to measure in our protocol (Roberts 2016),
for example, cognitive functioning and quality of life. Laan 2010
reported data for cognitive functioning but they were unusable;
neither trial reported data for quality if life. We also had to use
proxies for some important outcomes, for example, no trial directly
reported ’clinically important changes’ in global state so we used
the reported outcome ’necessitating change in dose or type of
antipsychotics’. Considering how inexpensive the intervention is,
and how expensive the potential outcomes are, it is surprising that
there is no reporting of economic costs.
9. Unused outcomes
We were unable to use outcome data on TH 1/TH 2 cytokine ratios
from Laan 2010, because these data were skewed. In correspon-
dence, Laan described that participants were unwilling to have
blood samples drawn and that data from all endpoints could not
be retrieved.
We were unable to use the cognitive test results from the Rey
Auditory Verbal Learning Test, the Purdue Pegboard Test, the
HQ Continuous Performance Test (Rosvold 1956), and the Trail
Making Test (Mezzich 1980) in Laan 2010 because either they
were not reported or available in sufficient detail.
Excluded studies
We excluded one study because there was no indication that it was
randomised and the measured outcomes were not relevant this re-
view (Rasheed 1992). This study measured blood levels of chlor-
promazine and interactions of aspirin in the metabolism of chlor-
promazine in people with schizophrenia compared with healthy
men. The authors of this study suggested that aspirin might pro-
long or enhance the therapeutic effects of chlorpromazine by slow-
ing down its metabolism.
Studies awaiting assessment
Weiser 2012 and Weiser 2016 were both randomised, parallel
studies comparing antipsychotic medication and adjunct aspirin
with antipsychotic medication and adjunct placebo. Weiser 2016
may be a subset of Weiser 2012. We contacted the authors of these
studies; Weiser 2016 replied that data from their study were not
usable yet.
Ongoing studies
There are four ongoing studies of the higher 1000 mg/day
dose of aspirin with 240 participants. Data from these studies
would substantially improve the evidence base, especially for spe-
cific outcomes such as immunological markers and global state.
NCT02047539 kindly replied to our email, saying that this study
was still recruiting participants. NCT02685748 kindly replied
that 17 participants were enrolled for the study, but no data were
available at this time. We have not yet received no replies from
IRCT201108197373N1 and IRCT201109287660N1.
Risk of bias in included studies
See the relevant ’Risk of bias’ tables in the Characteristics of
included studies table; Figure 2; and Figure 3.
Allocation
Both of the included studies stated they were randomised and used
computer-generated random sequences to allocate participants
and were at low risk of this bias (Attari 2017; Laan 2010). Nei-
ther publication reported sufficient information on the method
of allocation concealment but, in correspondence, the authors of
Laan 2010 kindly provided further details (low risk of bias). Attari
2017 was at unclear risk of bias.
Blinding
Both studies explicitly referred to how participants and assessors
were blinded and were at low risk of bias (Attari 2017; Laan 2010).
Incomplete outcome data
There was little evidence of attrition bias (low risk of attrition bias).
In Attari 2017, all participants completed the study. In Laan 2010,
12 participants left the study early and used LOCF to impute the
missing data.
Selective reporting
The included studies were at high or unclear risk of reporting bias.
This was due to either incomplete reporting of expected outcomes
(high risk; Laan 2010) or retroactive registration of the protocol
(unclear risk; Attari 2017).
Other potential sources of bias
Attari 2017 contained many apparent typographical errors and
inconsistencies in the results tables which we have detailed in the
Characteristics of included studies table (high risk of other bias).
Two review authors (EP and LS) contacted the authors to clarify
these inconsistencies but have not yet received a reply. Laan 2010
was at low risk of other bias.
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Effects of interventions
See: Summary of findings for the main comparison Aspirin plus
antipsychotics compared to placebo plus antipsychotics for people
with schizophrenia
1. Aspirin plus antipsychotics versus placebo plus
antipsychotics
Both included studies randomised participants to receive aspirin
or placebo, in addition to their regular antipsychotic medication.
1.1 Global state: any change - unspecified problem
necessitating change in dose or type of antipsychotics -
medium term
Laan 2010 reported data on the need to change dose or type of
antipsychotic. There was no clear difference between treatment
groups for this outcome (RR 0.75, 95% CI 0.30 to 1.88; studies
= 1; participants = 70; very low-quality evidence; Analysis 1.1).
1.2 Mental state: 1. General - mean endpoint score (PANSS
total, high = poor)
Both included studies reported on general mental state using
PANSS total endpoint scores (Analysis 1.2; Attari 2017; Laan
2010).
1.2.1 Short term
At short term, there was no clear difference in endpoint scores
(MD -1.84, 95% CI -7.55 to 3.87; studies = 2; participants =
130). This subgroup had moderate levels of heterogeneity (Chi2
= 2.1; degrees of freedom (df ) = 1.0; P = 0.15; I2 = 52%).
1.2.2 Medium term
By eight to 24 weeks, those participants allocated adjunct aspirin
had clearly better PANSS total endpoint scores (MD -6.56, 95%
CI -12.04 to -1.08; studies = 2; participants = 130; very low-
quality evidence).
1.3 Mental state: 2. Specific - negative symptoms - mean
endpoint score (PANSS negative, high = poor)
Both included studies reported negative symptoms using PANSS
negative (Analysis 1.3; Attari 2017; Laan 2010).
1.3.1 Short term
In the short term, there was no clear difference between the two
treatment groups (MD -0.79, 95% CI -2.85 to 1.27; studies = 2;
participants = 130).
1.3.2 Medium term
This equivocal result held true for the medium term (MD -1.81,
95% CI -3.64 to 0.01; studies = 2; participants = 130).
1.4 Mental state: 3. Specific - positive symptoms - mean
endpoint score (PANSS positive, high = poor)
Both included studies reported on positive symptoms using
PANSS positive (Analysis 1.4; Attari 2017; Laan 2010).
1.4.1 Short term
For positive symptom scores, we found no evidence that adjunct
aspirin was clearly different in its effects compared with adjunct
placebo (MD -0.87, 95% CI -2.62 to 0.89; studies = 2; participants
= 130).
1.4.2 Medium term
By eight to 24 weeks, there was a clear difference between adjunct
aspirin and adjunct placebo, favouring adjunct aspirin group (MD
-3.39, 95% CI -5.08 to -1.70; studies = 2; participants = 130), but
heterogeneity was very high (Chi2 = 5.63; df = 1.0; P = 0.02; I2 =
82%).
1.5 Leaving the study early: short-term
Both included studies reported numbers of participants leaving
the study early (Analysis 1.5; Attari 2017; Laan 2010).
1.5.1 Any reason
When it came to leaving the study early for any reason, there was
no evidence of a clear difference between the two treatment groups
(RR 1.12, 95% CI 0.40 to 3.14; studies = 2; participants = 130;
very low-quality evidence).
1.5.2 Gastrointestinal complaint - mild
There was no clear difference between adjunct aspirin and adjunct
placebo for leaving the study early because of mild gastric com-
plaints (RR 7.82, 95% CI 0.42 to 146.05; studies = 1; participants
= 70).
1.5.3 Lack of motivation
There was no clear difference between adjunct aspirin and adjunct
placebo for leaving the study early due to ’lack of motivation’ (RR
0.67, 95% CI 0.17 to 2.60; studies = 1; participants = 70).
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1.5.4 Referral to other centre
There was no clear difference between adjunct aspirin and adjunct
placebo for referral to other centre (RR 0.37, 95% CI 0.02 to
8.84; studies = 1; participants = 70).
1.6 Adverse events: 1. Gastrointestinal - dyspeptic
symptoms (Likert scale for dyspeptic complaints)
Laan 2010 reported incidence of dyspeptic symptoms where par-
ticipants as well as assessors indicated the seriousness of these symp-
toms (Analysis 1.6).
1.6.1 Self-assessed - as ’very serious’
There was no clear difference between adjunct aspirin and adjunct
placebo for ’very serious’ gastrointestinal events (RR 3.35, 95%
CI 0.14 to 79.59; studies = 1; participants = 70).
1.6.2 Self-assessed - as ’serious’
There was no clear difference between adjunct aspirin and adjunct
placebo for ’serious’ gastrointestinal events (RR 0.22, 95% CI 0.01
to 4.49; studies = 1; participants = 70).
1.6.3 Self-assessed - as ’moderate’
There was no clear difference between adjunct aspirin and adjunct
placebo for ’moderate’ gastrointestinal events (RR 1.03, 95% CI
0.55 to 1.94; studies = 1; participants = 70; very low-quality evi-
dence)
1.6.4 Researcher assessed - needing medical attention
because of gastrointestinal complaint
No participant in either of the groups needed medical attention
because of a gastrointestinal complaint (risk difference (RD) 0.00
95% CI -0.05 to 0.05; studies = 1; participants = 70).
1.7 Adverse events: 2. Other
Both included studies reported data for ’other’ types of adverse
events (Analysis 1.7; Attari 2017; Laan 2010).
1.7.1 General - any adverse events - as defined by each study
There was no clear difference between adjunct aspirin and adjunct
placebo for non-specific adverse events of any type (RR 0.56, 95%
CI 0.11 to 2.86; studies = 2; participants = 130).
1.7.2 Specific - attempted suicide
There was no clear difference between adjunct aspirin and adjunct
placebo for this serious event (RR 1.12, 95% CI 0.07 to 17.22;
studies = 1; participants = 70).
1.7.3 Specific - suicidal thoughts
There was no clear difference between adjunct aspirin and adjunct
placebo for suicidal thoughts (RR 1.12, 95% CI 0.07 to 17.22;
studies = 1; participants = 70).
1.7.4 Specific - requiring daily routine restructuring
There was no clear difference between adjunct aspirin and adjunct
placebo for this outcome (RR 0.37, 95% CI 0.02 to 8.84; studies
= 1; participants = 70).
1.8 Service use: change in hospital status
Laan 2010 reported service use data as ’change in hospital status’
(Analysis 1.8).
1.8.1 Admitted to closed ward - because of suicidal thoughts
There was no clear difference between the treatment groups for this
outcome (RR 1.12, 95% CI 0.07 to 17.22; studies = 1; participants
= 70).
1.8.2 Admitted to open ward - for daily routine restructuring
There was no clear difference between adjunct aspirin and adjunct
placebo for this outcome (RR 0.37, 95% CI 0.02 to 8.84; studies
= 1; participants = 70).
1.8.3 Any change in hospital status
There was no clear difference between the treatment groups for
’any change in hospital status’ (RR 0.56, 95% CI 0.05 to 5.90;
studies = 1; participants = 70; very low-quality evidence).
D I S C U S S I O N
Summary of main results
See Summary of findings for the main comparison.
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1. Aspirin plus antipsychotics compared to placebo
plus antipsychotics for people with schizophrenia
1.1 Global state: any change - unspecified problem
necessitating change in dose or type of antipsychotics -
medium term
No study reported the prespecified binary global state outcome
we had stipulated in our protocol (clinically important change in
global state; Roberts 2016). The above outcome is a proxy and
we downgraded the quality of evidence rating because of this. We
considered whether ’clinically important change in global state’
would be unreasonable to expect from trials but continued to
feel that such a simple and useful outcome could be expected.
Currently there is no indication that additional aspirin helps avoid
or increases the need for antipsychotic change (RR 0.75, 95%
CI 0.30 to 1.88; studies = 1; participants = 70; very low-quality
evidence).
1.2 Mental state: 1. General - mean endpoint score - total
(PANSS, high = poor) - medium term
The mental state outcome reported by the trials was a proxy for
what we had intended to report (clinically important change in
mental state). The fine-grain measure of the PANSS mean end-
point scores reported some suggestion of an improvement in men-
tal state scores for the aspirin group but the meaning of this for
day-to-day care was not clear to us and was not explained in the
trial (MD -6.56, 95% CI -12.04 to -1.08; studies = 2; participants
= 130; very low-quality evidence).
1.3 Leaving the study early: short-term - any reason
Less than 10% of participants in each group left the study early
- at around three months - but there was no clear difference be-
tween the groups (RR 1.12, 95% CI 0.40 to 3.14; studies = 2;
participants = 130; very low-quality evidence). This result suggests
people with schizophrenia did not find adding aspirin to antipsy-
chotic treatment unacceptable, but data were very limited quality.
1.4 Adverse events: Gastrointestinal - dyspeptic symptoms -
self assessed - ’moderate’
There is an enduring concern with aspirin that it is associated
with a risk of gastric problems. These short trials did not highlight
a clear difference (RR 1.03, 95% CI 0.55 to 1.94; studies = 1;
participants = 70; very low-quality evidence), but data were of very
limited quality, and both trials protected their participants from
gastric upset by giving pantoprazole or omeprazole.
1.5 Service use: change in hospital status - any change
Reported data suggested adding aspirin to regular antipsychotics
did not have a clear effect on ’change in a person’s hospital status’
(positive or negative was not clear from the report) (RR 0.56, 95%
CI 0.05 to 5.90; studies = 1; participants = 70; very low-quality
data). However, these data were few and very low quality and,
therefore, no conclusion about a difference could be drawn at this
point.
1.6 Missing data
1.6.1 Cognitive functioning
At this point, no data related to this important outcome could be
included in the analysis. There were data recorded and the authors
of Laan 2010 kindly attempted to find usable data but were unable
to retrieve them. This is an example of where data for outcomes,
thought to be important enough to gather from participants are
lost (Chalmers 2009).
1.6.2 Quality of life
At this point, no trial attempted to measure this outcome that is
important to service users. Quality of life was less measured in
trials of the last century, but now such outcomes are to be expected
to be routine and for them not to be included could suggest service
user participation in trial design was absent.
Overall completeness and applicability of
evidence
1. Completeness
We know randomised trials attempting to test the value of adding
aspirin to routine use of antipsychotic treatment have taken place.
We also know that there are unpublished data within these original
trials that could have added to the evidence. Despite the kind ef-
forts of the Laan 2010 authors, not all of these could be found. Fur-
thermore, we know of fully unpublished trials which have gained
informed consent, been undertaken and completed, and not re-
ported at all (Weiser 2012; Weiser 2016). Therefore, the data we
presented here are only part of the complete picture already in
existence.
Even when we did have numerical data to report, these were from
very small studies with limited duration. No outcome we reported
was a definitive finding. All outcome data were grossly incomplete
should clinicians, researchers or recipients of care feel the addition
of aspirin to medication be an important question. If this story is
to be completed, then much larger, longer, clinically meaningful
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trials should be undertaken, which should be clearly reported and
disseminated.
2. Applicability
The two small studies included in this review included people with
schizophrenia who had been diagnosed using DSM-IV criteria.
This could indicate that the population of these trials is made up
of patients who might be rare in every day clinical practice as many
people coming to clinic may not fall within the rigorous definition
of the DSM. One study was carried out in Iran and the other in
the Netherlands.
Aspirin is a globally available, low-cost drug and, therefore, an
accessible intervention.
Quality of the evidence
Overall the quality of the evidence was not good. Only two studies
with 130 participants could be included in the review. One of the
included studies had multiple inconsistencies in reporting values
(Attari 2017), and Laan 2010 demonstrated some evidence of se-
lective reporting. Attari 2017 reported that there were no adverse
events due to either aspirin or antipsychotics and did not publish
their protocol before the study. It seems unlikely, although not
impossible, that over a span of 10 weeks not one of the 60 partic-
ipants experienced an adverse event.
Poor reporting of several outcomes, including immunological pa-
rameters and cognitive outcomes, made the data impossible to
use within a meta-analysis. Neither study addressed several of the
outcomes review authors considered important and prespecified
as such in the protocol (Roberts 2016), including people’s quality
of life and the economic value of the intervention.
Potential biases in the review process
1. Missing studies
Every effort was made to identify relevant studies. It is possible
that we missed small, relevant studies but it seems unlikely that we
have missed any large studies that would have substantially altered
the conclusions of the review.
2. Introducing bias
We tried to be balanced in our appraisal of the evidence but could
have inadvertently introduced bias. Given the small number of
included studies, two review authors independently inspected all
citations obtained from the search and extracted the data to min-
imise bias. We welcome comments or criticisms.
Agreements and disagreements with other
studies or reviews
Sommer 2012 conducted a meta-analysis on non-steroidal anti-
inflammatory drugs for schizophrenia, including Laan 2010 and
four small studies on celecoxib. They focused on PANSS total and
subscale scores. This analysis showed very small positive effects for
non-steroidal anti-inflammatory drug; however, the few included
studies were small and potential publication bias was discussed.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
Theoretically aspirin may reduce inflammation associated with
schizophrenia and therefore reduce symptoms. However, studies
to date have provided insufficient evidence that aspirin actually
improves the symptoms or lives of people with schizophrenia.
Limited data show aspirin has a very narrow positive effect in the
medium term (eight weeks to six months) on the total PANSS
scale. However, at doses of 500 mg or 1000 mg, aspirin appears
to cause no more or no fewer significant adverse effects when
compared to placebo, but this is based on very few data. There-
fore, while aspirin is unlikely to effectively treat the symptoms of
schizophrenia, there are insufficient data to make final conclusions
about potential, long-term, adverse effects.
The publication of several studies that are currently either ongo-
ing or awaiting publication, with many more participants, would
improve the evidence base substantially. There are no usable data
available on whether aspirin affects aspects of cognitive function-
ing, service utilisation or levels of inflammation markers of people
with schizophrenia. In addition, no study attempted to measure
the impact of aspirin on people’s quality of life or its economic
value, which is relevant as aspirin is more affordable than most
novel treatments for schizophrenia. Therefore, in the context of a
randomised controlled trial, the intervention would be feasible.
2. For clinicians
The results of this review suggest that aspirin may improve the
mental state of people with schizophrenia in the medium term;
however, the small amount of data included in this analysis may
lead to an overestimation of the effects of aspirin.
Data on gastrointestinal complaints are very limited and there-
fore, no clear advice can be given on this very important topic.
Additionally, both trials gave gastric protection to participants and
none of the presently available studies provide data on long-term
effects. Therefore, it is unclear whether the benefits of prescribing
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aspirin over a longer period outside of the scope of a trial would
outweigh the possible risks and could raise ethical concerns.
3. For policy makers
For policy making, the limited available evidence does not suggest
a need for integrating adjunct aspirin as a mainstream intervention
for schizophrenia. No data on hospitalisation or functioning are
available and data on service use are very limited.
Implications for research
1. General
In order to prevent publication bias, protocols should be registered
prior to publication. In the context of this, and other interventions,
transparency and clear reporting of both methodology and results
makes it easier to assess validity of the results and facilitates the
reviewing process.
Binary data are usually easier to interpret and for all outcomes
that necessitate continuous outcomes, providing some measures
of variance is helpful.
To reduce uncertainty and expenditure of time, data presented in
graphs should be accompanied by tables or text references with ex-
act numbers and standard deviations (SD), for this review prefer-
ably as endpoint, and not as change scores. To enhance trans-
parency, and to gain access to the statistical values needed for this
review, Laan 2010 provided individual patient data from the trial.
This was very helpful to us, and systematic reviews could profit
from this practise in general.
2. Specific
2.1 Reviews
The protocol for a review on the effects of celecoxib was published
in the Cochrane Library (Akhondzadeh 2011). Celecoxib is an-
other potential NSAID intervention for schizophrenia that might
have an anti-inflammatory effect and therefore, the review for this
protocol should proceed. Additionally, aspirin and celecoxib data
might be investigated in the same context.
2.2 Trials
At the point of writing this review (July 2018) we know
of several important relevant studies. Weiser 2012 is com-
pleted and is thought to involve around 200 participants rel-
evant to this review. The four other ongoing studies may
also add hundreds of people’s data to the comparisons within
this review (IRCT201108197373N1; IRCT201109287660N1;
NCT02047539; NCT02685748). It is possible, that, within a few
years, the appended data will strengthen the evidence base to a
point where no more trials are needed. We eagerly await the re-
ports of the new trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Attari 2017
Methods Allocation: randomised, stratified by baseline PANSS scores
Blinding: triple
Design: parallel
Duration: 10 weeks
Participants Diagnosis: schizophrenia (DSM-IV-TR, clinical interview)
n = 60
Age: mean 33 years, SD 8
Gender: 39 men, 21 women
History: 2 years since onset of the disease. Patients with acute symptoms referred to
psychiatric clinic or emergency department
Inclusion criteria: aged 18-65 years, 2 years since onset
Exclusion criteria: unwillingness to participate; failure to follow-up for whatever reason;
unstable medical illness and medical history; contraindications for use of aspirin: asthma
or seasonal allergies, ulcers, kidney disease, active bleeding or clotting of blood disorders
such as haemophilia or bleeding, gout, nasal polyps, chronic use of NSAID, concomitant
use of corticosteroids for any reason; maternity
Setting: psychiatric clinic, single centre
Country: Iran
Interventions 1. Aspirin 325 mg/day + regular antipsychoticsa , omeprazole 20 mg/day. n = 20b
2. Aspirin 500 mg/day + regular antipsychoticsa , omeprazole 20 mg/day. n = 20
3. Placebo oral tablet daily + regular antipsychotics, omeprazole 20 mg/day. n = 20
Outcomes Mental state: PANSS total, negative, positivec
Adverse events: any
Leaving the study early: any reason
Unable to use:
Mental state: PANSS general psychopathology (not validated subscore)
Notes a Chlorpromazine, risperidone, olanzapine, haloperidol
bGroup receiving aspirin 325 mg is assumed to have a typo in Table 1: it says 20 male
participants, while all other numbers (total, percentages in gender distribution) point to
only 12 male participants. We assumed 12 participants for this group throughout this
review
cPANSS subscale scores did not always add up to the printed total in the tables. We
contacted authors for clarification but at the time of writing this report have not received
a reply
Risk of bias
Bias Authors’ judgement Support for judgement
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Attari 2017 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “The patients, through a number
table, were randomly divided”, “stratified
randomization was used”, “the random-
ization sequence was computer-generated,
with the randomization itself conducted
through SPSS20 software”, “Randomiza-
tion was done by one of the researchers,
who did not have a role in the treatment”
Comment: Table 2 indicated that base-
line PANSS scores differed significantly be-
tween the control and treatment groups.
However, the SDs of the groups overlapped
Allocation concealment (selection bias) Unclear risk Quote: “Allocation concealment was done
by the researcher, who was responsible
for the randomization. For this purpose,
the numbered envelops that contained the
name of the drugs … were used”, “partic-
ipants were referred to the hospital’s phar-
macy to obtain their drugs”, “A resident
of psychiatry generated the random allo-
cation sequence and enrolled participants,
and a co-worker psychologist assigned par-
ticipants to their interventions”
Comment: unclear if opaque, sealed en-
velopes used.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “placebo tablets had the same shape
and color of the effective aspirin”, “Drug
and placebo were coded A, B and C”, “Nei-
ther the examiner nor the clinician and the
patient were aware of the drug compounds”
Comment: see Materials and methods sec-
tion.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The PANSS scale was adminis-
tered on the first day, the end of the sixth
week and one month after cessation of as-
pirin or placebo”, “The outcomes of the
study were recorded by the psychiatrist of
the psychiatry ward, who made no other
contribution to the study”
Comment: no indications that adverse ef-
fects led to detection of allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participants lost to follow-up.
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Attari 2017 (Continued)
Selective reporting (reporting bias) Unclear risk Outcomes reported as stated in protocol,
but retrospective registration of protocol
Other bias High risk Reporting bias: inconsistent reporting of
values between number tables, minor mis-
takes with numbers not adding up correctly
(see ’Notes’ in Characteristics of included
studies table). Authors were contacted to
clarify the typographical errors, however,
there was no response
No adverse events recorded for aspirin or
antipsychotics, which is not impossible, but
unlikely
Laan 2010
Methods Allocation: randomised, stratified by psychiatric centre and immunological parameters
Blinding: double
Design: parallel
Duration: 3 months, preceded by 2 weeks placebo run-in
Participants Diagnosis: schizophrenia spectrum disorder (DSM-IV)
n = 70
Age: mean 31 years, SD 9 years
Gender: 58 men, 12 women
History: people taking antipsychotics
Inclusion criteria: PANSS score ≥ 60 (a minimum of 2 items had to have a score of ≥
4), aged 18-55 years
Exclusion criteria: illness duration > 5 years initially - lengthened to 10 years due to
slow enrolment, contraindications for aspirin or pantoprazole, significant somatic illness,
chronic NSAID use, corticosteroid use, pregnancy, change of type or dose of antipsy-
chotic in last 2 weeks
Setting: inpatients and outpatients, multicentre
Country: Netherlands
Interventions 1. Aspirin 1000 mg/day (oral) + regular antipsychoticsb , pantoprazole 40 mg/day. n =
33
2. Placebo daily (oral tablet) + regular antipsychotics, pantoprazole 40 mg/day. n = 37
Outcomes Global state: necessitating change in dose or type of antipsychotics
Mental state: PANSS total, negative, positive
Adverse events: gastrointestinal, any adverse events, attempted suicide, suicidal thoughts,
requiring daily routine restructuring
Leaving the study early: any reason, specific reasons
Service utilisation: change in hospital status (admitted to closed ward - because of suicidal
thoughts, admitted to open ward - for daily routine restructuring, any change)
Unable to use:
Mental state: PANSS general psychopathology (not validated subscore)
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Laan 2010 (Continued)
Cognitive functioning: changes in Rey Auditory Verbal Learning Test, Purdue Pegboard
Test, HQ Continuous Performance Test, Trail Making Test scores (not adequate outcome
data)
Inflammatory markers: TH 1/TH 2 cytokine ratios (only reported for baseline, missing
data from follow-up).a
Notes aAuthors were contacted to retrieve missing immunological and cognitive data. The
author kindly responded but these data could not be retrieved
b Olanzapine, clozapine and risperidone were described as the antipsychotics used by
most of the participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients will be randomised in a 1:
1 ratio to either supplementation of acetyl-
salicylic acid or placebo in addition to their
current antipsychotic treatment”; “a com-
puter generated list will be produced with
allocation codes in random order … using
permuted blocks”
Allocation concealment (selection bias) Low risk No information provided in publication.
The main author was contacted and kindly
replied that randomisation was done in the
university pharmacy, medications were la-
belled with randomly generated numbers,
and the link between the medication num-
ber and treatment group was kept in a safe
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Placebo will be identically pack-
aged, looking and tasting tablets”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All outcome assessments were per-
formed blind to the randomised treatment
status”
Comment: no evidence that blinding was
tested. The main author provided extra in-
formation that statistical analysis was per-
formed blind to the treatment status of each
cluster
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Twelve patients (17%), six in each
group, did not complete follow-up”
Comment: reasons for loss to follow-up
were well recorded. More participants in
the experimental arm left due to mild gas-
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Laan 2010 (Continued)
trointestinal adverse effects than in the
placebo arm. Used last observation carried
forward
Selective reporting (reporting bias) High risk TH 1/TH 2 cytokine ratios, a secondary out-
come specified in the protocol, were re-
ported at baseline for each group but not
for follow-up
Comment: contacted main author but data
could not be recovered
Other bias Low risk No other biases evident.
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; DSM-IV-TR: Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition, Text Revision; n: number of participants; NSAID: non-steroidal anti-inflammatory drug; PANSS:
Positive and Negative Symptom Scale; SD: standard deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Rasheed 1992 Allocation: not randomised
Participants: people with schizophrenia were compared with healthy individuals, all men
Outcomes: not of interest to this review: serum chlorpromazine concentration; serum salicylate concentration;
urinary excretion of drugs
Characteristics of studies awaiting assessment [ordered by study ID]
Weiser 2012
Methods Allocation: randomised
Blinding: not reported
Design: parallel
Duration: 16 weeks
Participants Diagnosis: schizophrenia or schizoaffective disorder
n = 400
Age: mean 42 years
Gender: 50% women
History: mean illness duration 13 years
Inclusion criteria: ≥ 4 (moderate) on CGI-S, ≥ 4 (moderate) on PANSS items (delusions, hallucinatory behaviours,
conceptual disorganisation or suspiciousness/persecution), total PANSS negative score > 18
Setting: multicentre
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Weiser 2012 (Continued)
Interventions 1. Aspirin 1000 mg/day (oral) + antipsychotics + pantoprazole 40 mg/day
2. Minocycline 200 mg/day (oral) + antipsychotics
3. Pramipexole 1.5 mg/day (oral) + antipsychotics
4. Placebo daily (oral) + antipsychotics
Outcomes Mental state: change in PANSS score (total and subscales: positive symptoms, negative symptoms)
Global state: change in CGI
Notes Awaiting useable data
Weiser 2016
Methods Allocation: randomised
Blinding: not reported
Design: parallel
Duration: 16 weeks
Participants Diagnosis: schizophrenia or schizoaffective disorder
n = 160
Age: mean about 41.5 years
History: mean duration of illness 9 years; mean baseline PANSS 101
Inclusion criteria: see Weiser 2012 inclusion criteria; high plasma CRP levels (> 3850 ng/mL)
Interventions 1. Aspirin 1000 mg/day + antipsychotics. n = 80
2. Placebo daily + antipsychotics. n = 80
Outcomes Mental state: change in PANSS score (total and subscales: positive symptoms, negative symptoms)
Cognitive functioning: “cognition”
Notes Probably a subset of Weiser 2012 participants who had high plasma CRP levels. Awaiting useable data
CGI-S: Clinical Global Impression - Severity scale; CRP: C-reactive protein; n: number of participants; PANSS: Positive and Negative
Symptom Scale.
Characteristics of ongoing studies [ordered by study ID]
IRCT201108197373N1
Trial name or title Efficacy of aspirin in treatment of schizophrenia
Methods Allocation: randomised
Blinding: triple
Duration: 8 weeks
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IRCT201108197373N1 (Continued)
Participants Diagnosis: schizophrenia according to DSM-IV criteria and clinical interview by psychiatrist
n = 60
Age: range 15-55 years
Gender: both
Inclusion criteria: PANSS score > 60
Exclusion criteria: pregnancy; substance abuse; sever physical disease such as kidney disease; coagulation
disorders; gastrointestinal disorders such as peptic ulcer; contraindications of aspirin and inhibitors of proton
pump
Country: Iran
Interventions 1. Aspirin 1000 mg/day + atypical antipsychotic
2. Placebo daily + atypical antipsychotic
Outcomes Mental state: PANSS
Adverse events: extrapyramidal and gastrointestinal adverse effects
Starting date Recruitment start date: 23 October 2011
Contact information Dr Hamidreza Jamilian, jamilian.hr@arakmu.ac.ir
Notes Protocol and outcome data not available. Attempted to contact author
IRCT201109287660N1
Trial name or title Effect of aspirin augmentation on cognitive and clinical symptoms of schizophrenic patients
Methods Allocation: randomised
Blinding: double
Duration: 12 weeks
Participants Diagnosis: schizophrenia according to DSM-IV criteria
n = 40
History: admitted to Ibn Sina hospital of Mashhad
Inclusion criteria: PANSS score > 60; duration of illness < 5 years and 1-3 episodes
Exclusion criteria: physical disease based on clinical examination; chronic use of NSAIDs; corticosteroid
use; pregnancy, contraindication for aspirin or omeprazole; other drug use (except for anticholinergics and
benzodiazepines)
Country: Iran
Interventions 1. Aspirin 1000 mg/day + risperidone dose started at 2 mg and increased to 6 mg or maximum dose tolerated
by patient
2. Placebo daily + risperidone dose same as group 1
Outcomes Mental state: PANSS
Cognitive functioning: Weschler, Wisconsin, Stroop, BPRS, Digit Span tests
Starting date Recruitment start date: 21 December 2013
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IRCT201109287660N1 (Continued)
Contact information ramresearch@mums.ac.ir
Notes Attempted to contact author to enquire about outcomes
NCT02047539
Trial name or title Randomized controlled trial of aspirin vs placebo in the treatment of patients with the clinical risk syndrome
for psychosis
Methods Allocation: randomised
Blinding: double
Duration: 12 weeks
Participants n = 40
Age: 19-35 years
Gender: both
Inclusion criteria: demonstrate adequate decisional capacity; meet ≥ 3 of the clinical high-risk symptoms
defined by Structured Interview for Prodromal Symptoms
Exclusion criteria: pre-existing gastrointestinal disease; heart disease; kidney disease; use of NSAIDs; hy-
persensitive to NSAID; coexisting unstable major medical illness; pregnant or breastfeeding; consume > 2
drinks of alcohol per day; have a blood clotting disorder; taking angiotensin-converting enzyme inhibitors;
acetazolamide; anticoagulants; anticonvulsants; beta-blockers; diuretics; methotrexate; oral hypoglycaemic;
uricosuric agents; history of substance abuse in the past 3 months or dependence in past 6 months
Country: USA
Interventions 1. Aspirin 1000 mg/day
2. Placebo 1000 mg/day
Outcomes Inflammation markers: laboratory studies of inflammation markers and genetic samples
Not used: mental state: Scale of Prodromal Symptoms (written by 1 of the trialists)
Starting date March 2014
Contact information Dr Scott W Woods; scott.woods@yale.edu
Notes Contacted author and the study is still registering participants
Funding: Yale University
NCT02685748
Trial name or title Aspirin in young psychotic patients
Methods Allocation: randomised
Blinding: double
Duration: 6 weeks
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NCT02685748 (Continued)
Participants Diagnosis: F 20 to F 29 according to ICD-10 criteria
n = 100
Age: 18-28 years
Gender: both
Inclusion criteria: duration of illness < 7 years
Exclusion criteria: substance abuse; primary cognitive impairment; contraindications and special caution for
aspirin and pantoprazole: hypersensitivity to aspirin and other NSAIDs or panto ulcers, gastritis, pregnancy,
haemophilia, bleeding disorders, gout, asthma, COPD, bronchospasm induced by NSAIDs, angio-oedema,
haemolytic anaemia, use of warfarin or methotrexate, diabetes, reduced function of liver or kidney (or both)
, heart failure, surgical/dental intervention, interactions with certain psychotropic drugs
Interventions 1. Aspirin 1000 mg/day (oral) + pantoprazole 40 mg/day (oral)
2. Placebo daily (oral)
Outcomes Cognitive functioning: change in Heidelberg Neurological Soft Signs scale; MoCA score
Mental state: change in PANSS total score and subscores
Inflammation markers: change in C-reactive proteins, white blood cell count, cytokine profile including Th1,
Th2, and Type-17 immune response
Starting date March 2016
Contact information Dr Dragana Pavicevic, gagapavicevic@yahoo.com
Notes Attempted to contact author to enquire about outcomes
Funding: Stanley Medical Institute
BPRS: Brief Psychiatric Rating Scale; COPD: chronic obstructive pulmonary disease; DSM-IV: Diagnostic and Statistical Manual
of Mental Disorders, 4th Edition; ICD-10: International Classification of Diseases 10th Revision; MoCA: Montreal Cognitive
Assessment scale; n: number of participants; NSAID: non-steroidal anti-inflammatory drug; PANSS: Positive and Negative Syndrome
Scale.
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D A T A A N D A N A L Y S E S
Comparison 1. Aspirin plus antipsychotics versus placebo plus antipsychotics)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: any change
- unspecified problem
necessitating change in dose
or type of antipsychotics -
medium term
1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.30, 1.88]
2 Mental state: 1. General - mean
endpoint score (Positive and
Negative Symptom Scale
(PANSS) total, high = poor)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Short term 2 130 Mean Difference (IV, Fixed, 95% CI) -1.84 [-7.55, 3.87]
2.2 Medium term 2 130 Mean Difference (IV, Fixed, 95% CI) -6.56 [-12.04, -1.08]
3 Mental state: 2. Specific -
negative symptoms - mean
endpoint score (PANSS
negative, high = poor)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Short term 2 130 Mean Difference (IV, Fixed, 95% CI) -0.79 [-2.85, 1.27]
3.2 Medium term 2 130 Mean Difference (IV, Fixed, 95% CI) -1.81 [-3.64, 0.01]
4 Mental state: 3. Specific - positive
symptoms - mean endpoint
score (PANSS positive, high =
poor)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Short term 2 130 Mean Difference (IV, Fixed, 95% CI) -0.87 [-2.62, 0.89]
4.2 Medium term 2 130 Mean Difference (IV, Fixed, 95% CI) -3.39 [-5.08, -1.70]
5 Leaving the study early:
short-term
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Any reason 2 130 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.40, 3.14]
5.2 Due to gastrointestinal
complaint - mild
1 70 Risk Ratio (M-H, Fixed, 95% CI) 7.82 [0.42, 146.05]
5.3 Lack of motivation 1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.17, 2.60]
5.4 Referral to other centre 1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.02, 8.84]
6 Adverse events: 1.
Gastrointestinal - dyspeptic
symptoms (Likert scale for
dyspeptic complaints)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Self-assessed - as ’very
serious’
1 70 Risk Ratio (M-H, Fixed, 95% CI) 3.35 [0.14, 79.59]
6.2 Self-assessed - as ’serious’ 1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.01, 4.49]
6.3 Self-assessed - as
’moderate’
1 70 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.55, 1.94]
6.4 Researcher assessed -
needing medical attention
because of gastrointestinal
complaint
1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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7 Adverse events: 2. Other 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 General - any adverse
events - as defined by each
study
2 130 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.11, 2.86]
7.2 Specific - attempted
suicide
1 70 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.07, 17.22]
7.3 Specific - suicidal thoughts 1 70 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.07, 17.22]
7.4 Specific - requiring daily
routine restructuring
1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.02, 8.84]
8 Service use: change in hospital
status
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Admitted to closed ward -
because of suicidal thoughts
1 70 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.07, 17.22]
8.2 Admitted to open ward -
for daily routine restructuring
1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.02, 8.84]
8.3 Any change in hospital
status
1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.05, 5.90]
Analysis 1.1. Comparison 1 Aspirin plus antipsychotics versus placebo plus antipsychotics), Outcome 1
Global state: any change - unspecified problem necessitating change in dose or type of antipsychotics -
medium term.
Review: Acetylsalicylic acid (aspirin) for schizophrenia
Comparison: 1 Aspirin plus antipsychotics versus placebo plus antipsychotics)
Outcome: 1 Global state: any change unspecified problem necessitating change in dose or type of antipsychotics medium term
Study or subgroup
Aspirin +
antipsy-
chotics
Placebo +
antipsy-
chotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Laan 2010 6/33 9/37 100.0 % 0.75 [ 0.30, 1.88 ]
Total (95% CI) 33 37 100.0 % 0.75 [ 0.30, 1.88 ]
Total events: 6 (Aspirin + antipsychotics), 9 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours aspirin Favours placebo
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Analysis 1.2. Comparison 1 Aspirin plus antipsychotics versus placebo plus antipsychotics), Outcome 2
Mental state: 1. General - mean endpoint score (Positive and Negative Symptom Scale (PANSS) total, high =
poor).
Review: Acetylsalicylic acid (aspirin) for schizophrenia
Comparison: 1 Aspirin plus antipsychotics versus placebo plus antipsychotics)
Outcome: 2 Mental state: 1. General mean endpoint score (Positive and Negative Symptom Scale (PANSS) total, high = poor)
Study or subgroup
Aspirin +
antipsy-
chotics
Placebo +
antipsy-
chotics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Short term
Attari 2017 40 106 (29.2595) 20 98.25 (24.86) 16.2 % 7.75 [ -6.42, 21.92 ]
Laan 2010 33 67.545 (15.007) 37 71.24 (11.068) 83.8 % -3.70 [ -9.94, 2.54 ]
Subtotal (95% CI) 73 57 100.0 % -1.84 [ -7.55, 3.87 ]
Heterogeneity: Chi2 = 2.10, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.63 (P = 0.53)
2 Medium term
Attari 2017 40 75.175 (23.6111) 20 85.1 (23.41) 18.9 % -9.92 [ -22.53, 2.68 ]
Laan 2010 33 61.818 (14.085) 37 67.59 (11.588) 81.1 % -5.78 [ -11.86, 0.31 ]
Subtotal (95% CI) 73 57 100.0 % -6.56 [ -12.04, -1.08 ]
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Chi2 = 1.37, df = 1 (P = 0.24), I2 =27%
-20 -10 0 10 20
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Analysis 1.3. Comparison 1 Aspirin plus antipsychotics versus placebo plus antipsychotics), Outcome 3
Mental state: 2. Specific - negative symptoms - mean endpoint score (PANSS negative, high = poor).
Review: Acetylsalicylic acid (aspirin) for schizophrenia
Comparison: 1 Aspirin plus antipsychotics versus placebo plus antipsychotics)
Outcome: 3 Mental state: 2. Specific negative symptoms mean endpoint score (PANSS negative, high = poor)
Study or subgroup
Aspirin +
antipsy-
chotics
Placebo +
antipsy-
chotics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Short term
Attari 2017 40 27.275 (7.9734) 20 25.7 (9.95) 16.9 % 1.57 [ -3.44, 6.59 ]
Laan 2010 33 17.242 (4.697) 37 18.51 (4.963) 83.1 % -1.27 [ -3.53, 0.99 ]
Subtotal (95% CI) 73 57 100.0 % -0.79 [ -2.85, 1.27 ]
Heterogeneity: Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Medium term
Attari 2017 40 18.3 (6.4358) 20 21.8 (8.87) 17.4 % -3.50 [ -7.87, 0.87 ]
Laan 2010 33 15.788 (4.234) 37 17.24 (4.327) 82.6 % -1.45 [ -3.46, 0.55 ]
Subtotal (95% CI) 73 57 100.0 % -1.81 [ -3.64, 0.01 ]
Heterogeneity: Chi2 = 0.69, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.052)
Test for subgroup differences: Chi2 = 0.53, df = 1 (P = 0.47), I2 =0.0%
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Analysis 1.4. Comparison 1 Aspirin plus antipsychotics versus placebo plus antipsychotics), Outcome 4
Mental state: 3. Specific - positive symptoms - mean endpoint score (PANSS positive, high = poor).
Review: Acetylsalicylic acid (aspirin) for schizophrenia
Comparison: 1 Aspirin plus antipsychotics versus placebo plus antipsychotics)
Outcome: 4 Mental state: 3. Specific positive symptoms mean endpoint score (PANSS positive, high = poor)
Study or subgroup
Aspirin +
antipsy-
chotics
Placebo +
antipsy-
chotics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Short term
Attari 2017 40 23.75 (5.7628) 20 25.1 (6.74) 26.0 % -1.35 [ -4.80, 2.10 ]
Laan 2010 33 16.061 (4.905) 37 16.76 (3.642) 74.0 % -0.70 [ -2.74, 1.35 ]
Subtotal (95% CI) 73 57 100.0 % -0.87 [ -2.62, 0.89 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.33)
2 Medium term
Attari 2017 40 15.125 (4.7494) 20 21.8 (6.48) 28.0 % -6.68 [ -9.87, -3.48 ]
Laan 2010 33 14.212 (4.504) 37 16.32 (3.953) 72.0 % -2.11 [ -4.11, -0.12 ]
Subtotal (95% CI) 73 57 100.0 % -3.39 [ -5.08, -1.70 ]
Heterogeneity: Chi2 = 5.63, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 3.92 (P = 0.000087)
Test for subgroup differences: Chi2 = 4.11, df = 1 (P = 0.04), I2 =76%
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Analysis 1.5. Comparison 1 Aspirin plus antipsychotics versus placebo plus antipsychotics), Outcome 5
Leaving the study early: short-term.
Review: Acetylsalicylic acid (aspirin) for schizophrenia
Comparison: 1 Aspirin plus antipsychotics versus placebo plus antipsychotics)
Outcome: 5 Leaving the study early: short-term
Study or subgroup
Aspirin +
antipsy-
chotics
Placebo +
antipsy-
chotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any reason
Attari 2017 0/40 0/20 Not estimable
Laan 2010 6/33 6/37 100.0 % 1.12 [ 0.40, 3.14 ]
Subtotal (95% CI) 73 57 100.0 % 1.12 [ 0.40, 3.14 ]
Total events: 6 (Aspirin + antipsychotics), 6 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
2 Due to gastrointestinal complaint mild
Laan 2010 3/33 0/37 100.0 % 7.82 [ 0.42, 146.05 ]
Subtotal (95% CI) 33 37 100.0 % 7.82 [ 0.42, 146.05 ]
Total events: 3 (Aspirin + antipsychotics), 0 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
3 Lack of motivation
Laan 2010 3/33 5/37 100.0 % 0.67 [ 0.17, 2.60 ]
Subtotal (95% CI) 33 37 100.0 % 0.67 [ 0.17, 2.60 ]
Total events: 3 (Aspirin + antipsychotics), 5 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
4 Referral to other centre
Laan 2010 0/33 1/37 100.0 % 0.37 [ 0.02, 8.84 ]
Subtotal (95% CI) 33 37 100.0 % 0.37 [ 0.02, 8.84 ]
Total events: 0 (Aspirin + antipsychotics), 1 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Chi2 = 2.65, df = 3 (P = 0.45), I2 =0.0%
0.01 0.1 1 10 100
Favours aspirin Favours placebo
43Acetylsalicylic acid (aspirin) for schizophrenia (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 Aspirin plus antipsychotics versus placebo plus antipsychotics), Outcome 6
Adverse events: 1. Gastrointestinal - dyspeptic symptoms (Likert scale for dyspeptic complaints).
Review: Acetylsalicylic acid (aspirin) for schizophrenia
Comparison: 1 Aspirin plus antipsychotics versus placebo plus antipsychotics)
Outcome: 6 Adverse events: 1. Gastrointestinal dyspeptic symptoms (Likert scale for dyspeptic complaints)
Study or subgroup
Aspirin +
antipsy-
chotics
Placebo +
antipsy-
chotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Self-assessed as ’very serious’
Laan 2010 1/33 0/37 100.0 % 3.35 [ 0.14, 79.59 ]
Subtotal (95% CI) 33 37 100.0 % 3.35 [ 0.14, 79.59 ]
Total events: 1 (Aspirin + antipsychotics), 0 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
2 Self-assessed as ’serious’
Laan 2010 0/33 2/37 100.0 % 0.22 [ 0.01, 4.49 ]
Subtotal (95% CI) 33 37 100.0 % 0.22 [ 0.01, 4.49 ]
Total events: 0 (Aspirin + antipsychotics), 2 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
3 Self-assessed as ’moderate’
Laan 2010 12/33 13/37 100.0 % 1.03 [ 0.55, 1.94 ]
Subtotal (95% CI) 33 37 100.0 % 1.03 [ 0.55, 1.94 ]
Total events: 12 (Aspirin + antipsychotics), 13 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
4 Researcher assessed needing medical attention because of gastrointestinal complaint
Laan 2010 0/33 0/37 Not estimable
Subtotal (95% CI) 33 37 Not estimable
Total events: 0 (Aspirin + antipsychotics), 0 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 1.53, df = 2 (P = 0.47), I2 =0.0%
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Analysis 1.7. Comparison 1 Aspirin plus antipsychotics versus placebo plus antipsychotics), Outcome 7
Adverse events: 2. Other.
Review: Acetylsalicylic acid (aspirin) for schizophrenia
Comparison: 1 Aspirin plus antipsychotics versus placebo plus antipsychotics)
Outcome: 7 Adverse events: 2. Other
Study or subgroup
Aspirin +
antipsy-
chotics
Placebo +
antipsy-
chotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 General any adverse events as defined by each study
Attari 2017 0/40 0/20 Not estimable
Laan 2010 2/33 4/37 100.0 % 0.56 [ 0.11, 2.86 ]
Subtotal (95% CI) 73 57 100.0 % 0.56 [ 0.11, 2.86 ]
Total events: 2 (Aspirin + antipsychotics), 4 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
2 Specific attempted suicide
Laan 2010 1/33 1/37 100.0 % 1.12 [ 0.07, 17.22 ]
Subtotal (95% CI) 33 37 100.0 % 1.12 [ 0.07, 17.22 ]
Total events: 1 (Aspirin + antipsychotics), 1 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
3 Specific suicidal thoughts
Laan 2010 1/33 1/37 100.0 % 1.12 [ 0.07, 17.22 ]
Subtotal (95% CI) 33 37 100.0 % 1.12 [ 0.07, 17.22 ]
Total events: 1 (Aspirin + antipsychotics), 1 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
4 Specific requiring daily routine restructuring
Laan 2010 0/33 1/37 100.0 % 0.37 [ 0.02, 8.84 ]
Subtotal (95% CI) 33 37 100.0 % 0.37 [ 0.02, 8.84 ]
Total events: 0 (Aspirin + antipsychotics), 1 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Chi2 = 0.45, df = 3 (P = 0.93), I2 =0.0%
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Analysis 1.8. Comparison 1 Aspirin plus antipsychotics versus placebo plus antipsychotics), Outcome 8
Service use: change in hospital status.
Review: Acetylsalicylic acid (aspirin) for schizophrenia
Comparison: 1 Aspirin plus antipsychotics versus placebo plus antipsychotics)
Outcome: 8 Service use: change in hospital status
Study or subgroup
Aspirin +
antipsy-
chotics
Placebo +
antipsy-
chotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Admitted to closed ward because of suicidal thoughts
Laan 2010 1/33 1/37 100.0 % 1.12 [ 0.07, 17.22 ]
Subtotal (95% CI) 33 37 100.0 % 1.12 [ 0.07, 17.22 ]
Total events: 1 (Aspirin + antipsychotics), 1 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
2 Admitted to open ward for daily routine restructuring
Laan 2010 0/33 1/37 100.0 % 0.37 [ 0.02, 8.84 ]
Subtotal (95% CI) 33 37 100.0 % 0.37 [ 0.02, 8.84 ]
Total events: 0 (Aspirin + antipsychotics), 1 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 Any change in hospital status
Laan 2010 1/33 2/37 100.0 % 0.56 [ 0.05, 5.90 ]
Subtotal (95% CI) 33 37 100.0 % 0.56 [ 0.05, 5.90 ]
Total events: 1 (Aspirin + antipsychotics), 2 (Placebo + antipsychotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 0.29, df = 2 (P = 0.87), I2 =0.0%
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Date Event Description
8 March 2018 Amended Search was updated and 1 new study was added to Ongoing studies section
29 June 2017 Amended Search updated and 3 references were added to Studies Awaiting Classification section of the review.
Please consider that one of the references reports two studies that’s why I have added it twice under
two different study names. one of the references reports a new study
24 March 2016 Amended Search updated and 6 studies (16 references) were added to ’Studies Awaiting Classification’ section
of the review
C O N T R I B U T I O N S O F A U T H O R S
LS: independent data extraction, review writing, data analysis and contacting study authors.
EP: independent data extraction, review writing, data analysis and contacting study authors.
JF: independent data extraction.
FS: designing search strategies, protocol development and data collection, checking of final draft.
D E C L A R A T I O N S O F I N T E R E S T
LS: none.
EP: none.
JF: none.
FS: none.
S O U R C E S O F S U P P O R T
Internal sources
• The University of Nottingham, UK.
Employed review author TR at time of writing protocol; however, TR wrote the protocol in her own time.
Employs FS as Cochrane Schizophrenia’s Information specialist: however, FS helped with the review in his own time.
ES and JF were students at the time of writing this review.
• Hochschule Furtwangen University, Furtwangen, Germany.
Review author LS was a student as this University at the time of writing the review.
• NIHR, UK.
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External sources
• National Institute for Health Research (NIHR Systematic Review Fellowship, RM-SR-2017-09-028), UK.
Grant awarded to review author LS.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
We updated the methods section to reflect latest methods employed by Cochrane Schizophrenia and their methods template. We
clarified that quality of life outcome for the ’Summary of findings’ table would ideally be ’clinically important change’ as is the case for
the other outcomes.
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